Hikma Pharmaceuticals (LON:HIK) Stock Passes Above Two Hundred Day Moving Average – Here’s What Happened

Shares of Hikma Pharmaceuticals PLC (LON:HIK) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,448.74 and traded as high as GBX 1,575. Hikma Pharmaceuticals shares last traded at GBX 1,557.81, with a volume of 24,302,965 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Berenberg Bank reiterated a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Jefferies Financial Group upped their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 195 price objective on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Finally, Citigroup reaffirmed a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of GBX 1,687.

Hikma Pharmaceuticals Trading Up 0.3%

The business’s 50-day moving average price is GBX 1,502.94 and its two-hundred day moving average price is GBX 1,448.74. The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27. The firm has a market cap of £3.28 billion, a price-to-earnings ratio of 8.61, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.